Patent · US Active

Prevention of pertussis using adenylate cyclase deficient Bordetella strains

US10046044B2 · kind B2 · utility

1Cited by

2References

9Claims

0Family size

Assignees

NATIONAL UNIVERSITY OF SINGAPORE · SG
Institut National de la Sante et de la Recherche Medicale (INSERM) · FR
INSTITUT PASTEUR DE LILLE · FR

Inventors

Sylvie Claudette Alonso · Singapore, SG
Rui Fen Annabelle Lim · Singapore, SG
Camille Locht · Wannehain, FR

Key dates

Filing date	Apr 3, 2017
Grant date	Aug 14, 2018
Priority date	—
Expiry date	Apr 3, 2037

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61K2039/522
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

A CyaA-deficient B. pertussis mutant was constructed and used in a vaccine. The pertussis-specific antibody profile and Th17 response induced by vaccination with the mutant was surprisingly comparable to that induced by B. pertussis strains not deficient in CyaA.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.